Department of Medicine, Harvard Medical School, Boston, Mass; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
Department of Medicine, Harvard Medical School, Boston, Mass; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
J Allergy Clin Immunol. 2023 Sep;152(3):700-710.e3. doi: 10.1016/j.jaci.2023.03.030. Epub 2023 Apr 15.
Aspirin-exacerbated respiratory disease (AERD) is the triad of asthma, nasal polyposis, and respiratory reactions to COX-1 inhibitors. Overproduction of cysteinyl leukotrienes and underproduction of prostaglandin E (PGE) are hallmarks of AERD. A mouse model predicted a key role for the thromboxane-prostanoid (TP) receptor in AERD.
Our aim was to determine whether ifetroban, a TP receptor antagonist, attenuates aspirin-induced respiratory symptoms in patients with AERD.
A total of 35 patients with AERD completed a 4-week double-blinded, placebo-controlled trial of ifetroban and underwent an oral aspirin challenge. The primary outcome was change in the provocative dose of aspirin that caused a 2-point increase in Total Nasal Symptom Score. Changes in lung function, eicosanoid levels, and platelet and mast cell activation were assessed. Cultured human nasal fibroblasts were stimulated with or without the TP agonist U46619 and assayed for prostanoid production.
Ifetroban was well tolerated in AERD and did not change the mean 2-point increase in Total Nasal Symptom Score (P = .763). Participants taking ifetroban had greater aspirin-induced nasal symptoms and a greater decline in FEV value than did participants receiving placebo (-18.8% ± 3.6% with ifetroban vs -8.4% ± 2.1% with placebo [P = .017]). Four weeks of ifetroban significantly increased urinary leukotriene E levels and decreased nasal PGE levels compared with placebo. Peak aspirin-induced urinary thromboxane levels correlated with peak urinary leukotriene E and prostaglandin D metabolite levels in participants taking ifetroban. U46119 significantly potentiated the production of PGE by cultured nasal fibroblasts from subjects with AERD but not by cultured nasal fibroblasts from controls without polypoid sinusitis.
Contrary to our hypothesis, TP receptor blockade worsened aspirin-induced reactions in AERD, possibly by exacerbating dysregulation of the eicosanoid system. TP signaling on stromal cells may be critical to maintaining PGE production when COX-2 function is low.
阿司匹林加重的呼吸道疾病(AERD)是哮喘、鼻息肉和对 COX-1 抑制剂的呼吸道反应的三联征。半胱氨酰白三烯的过度产生和前列腺素 E(PGE)的产生不足是 AERD 的标志。一种小鼠模型预测血栓素-前列腺素(TP)受体在 AERD 中起关键作用。
我们旨在确定是否特罗非班,一种 TP 受体拮抗剂,可减轻 AERD 患者阿司匹林引起的呼吸道症状。
35 例 AERD 患者完成了为期 4 周的特罗非班双盲、安慰剂对照试验,并接受了口服阿司匹林挑战。主要结局是引起总鼻部症状评分增加 2 分的阿司匹林激发剂量的变化。评估了肺功能、类花生酸水平以及血小板和肥大细胞的激活变化。用或不用 TP 激动剂 U46619 刺激培养的人鼻成纤维细胞,并检测前列腺素的产生。
特罗非班在 AERD 中耐受性良好,并未改变总鼻部症状评分增加 2 分的平均值(P=.763)。服用特罗非班的参与者比服用安慰剂的参与者出现更多的阿司匹林引起的鼻部症状和更大的 FEV 值下降(特罗非班组为-18.8%±3.6%,安慰剂组为-8.4%±2.1%[P=.017])。与安慰剂相比,特罗非班治疗 4 周后,尿白三烯 E 水平显著升高,鼻 PGE 水平显著降低。服用特罗非班的参与者中,阿司匹林引起的尿血栓素峰值与尿白三烯 E 和前列腺素 D 代谢物峰值相关。U46119 显著增强了 AERD 患者培养的鼻成纤维细胞产生的 PGE,但对无息肉性鼻窦炎的对照组培养的鼻成纤维细胞没有这种作用。
与我们的假设相反,TP 受体阻断剂加重了 AERD 中阿司匹林引起的反应,可能是通过加剧了类花生酸系统的失调。当 COX-2 功能低下时,TP 信号在基质细胞上可能对维持 PGE 产生至关重要。